Endonovo Therapeutics is a commercial stage developer of non-invasive medical devices that specialize in delivering their proprietary Electroceutical® Therapy. This therapy is designed to treat a range of inflammatory conditions, cardiovascular diseases, and central nervous system disorders. The Electroceutical® Therapy is FDA-Cleared for pain management and post-surgical edema, and it is also CE Marked for wound healing and pain management.

Additionally, it has CMS National Coverage for the treatment of chronic wounds. Endonovo's mission is encapsulated in the name itself, as Endonovo means to renew from within. They aim to develop safe and wearable non-invasive medical devices that utilize bioelectricity to restore crucial electrochemical processes.

These processes promote healing by triggering anti-inflammatory and growth factor cascades. With a focus on cardiovascular diseases and central nervous system disorders, the company's pipeline includes therapies for conditions like ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI), and multiple sclerosis. By combining innovative technology with comprehensive scientific studies, Endonovo strives to revolutionize the healthcare industry and improve patients' lives